Recent evidence suggests that the gut microbiome plays a crucial role in influencing responses to immune checkpoint inhibitors (ICIs), such as anti-PD-1 and anti-CTLA-4 therapies, which are widely used in cancer treatment. The gene discussed is CTLA4; the disease is cancer.